

VACCINAZIONI ANTI COVID-19

SERVIZI DI SUPPORTO



Pietro Di Comite
Direttore
Commerciale



Claudio Costanza
Team Leader - Client
Success Partners
Europe



Questo webinar sarà registrato,
l'audience sarà pertanto in modalità
di sola visualizzazione e ascolto



Seguirà un'e-mail contenente i
link al sondaggio e alla
registrazione del webinar

VACCINAZIONI ANTI COVID-19 SERVIZI DI SUPPORTO

Agenda



Claudio Costanza

- Servizi di sottoscrizione per aiutarvi ad affrontare le sfide presentate da COVID-19 e relative alle vaccinazioni



Pietro Di Comite

- Pianificazione e implementazione su misura di una strategia vaccinale



SONDAGGIO

Qual è la vostra principale sfida organizzativa nella gestione della pianificazione/ implementazione di una strategia e distribuzione dei vaccini anti COVID-19?


- Accesso ad informazioni affidabili e aggiornate
- Sensibilizzare i dipendenti sui benefici della vaccinazione
- Supporto e competenze pratiche esperte in tale pianificazione
- Mancanza di un supporto esperto nella definizione di un piano strategico
- Supporto nella distribuzione dei vaccini (medici, forniture se disponibili...)




VACCINAZIONI ANTI COVID-19: SERVIZI DI SUPPORTO

Fornire intelligence e consulenza allo staff e al management





VALUTAZIONE DEL QUADRO VACCINALE



Informazioni dettagliate sui vaccini in uso



INTERNATIONAL SOS

Monitor

Active Threat: COVID-19

Alerts

Locations

Reporting

My Company

Resources

David Heimerlin...

CONTACT US

Monitor / Active Threat: COVID-19

Location Insights

Intelligence & Forecasting

Related Materials

Scientific Update

Security Analysis & Forecasting

The Scientific Update is a weekly compendium of items relating mainly to immunity and vaccine development.

INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 26 MARCH 2021	Download document	26 Mar 2021 07:28 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 19 MARCH 2021	Download document	19 Mar 2021 08:40 GMT
INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 12 MARCH 2021	Download document	12 Mar 2021 11:29 GMT
INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 5 MARCH 2021	Download document	05 Mar 2021 11:00 GMT
INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 2 MARCH 2021	Download document	05 Mar 2021 10:57 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 26 FEBRUARY 2021	Download document	26 Feb 2021 09:08 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 19 FEBRUARY 2021_SG	Download document	19 Feb 2021 11:10 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 19 FEBRUARY 2021	Download document	19 Feb 2021 11:02 GMT

VALUTAZIONE
DEI RISCHI

Aggiornamenti scientifici sui vaccini

2019-nCoV > COVID-19 Vaccine

COVID-19 VACCINE

Vaccination against COVID-19 has begun in many countries. For detail on the situation in each country, see the relevant **country page on this website** (access restricted to Pandemic Information Service / Site Monitor subscribers*), and the **VACCINE DISTRIBUTION CHARTS** below. The **COVAX programme** aims to provide vaccine to at least 20% of the population of lower-income countries. *please contact your account manager if you do not have subscription and are interested in access

There are hundreds of vaccines continuing through clinical trials and approval processes (see **VACCINE TRACKERS** section below for links to websites that track development and approvals, **WHO Draft landscape and tracker of COVID-19 candidate vaccines**)

Vaccines in Use

- Bharat Biotech Covaxin
- CanSino Biologics (Convidicea)
- Gamaleya Sputnik V
- Moderna
- Oxford/ AstraZeneca (Covishield)
- Pfizer/BioNTech Comirnaty
- Sinopharm
- Sinovac CoronaVac

COVID-19 Vaccine FAQs

COVID-19 Vaccination Benefits Infographic

COVID-19 VACCINE FAQs

TRAVEL RESTRICTIONS FLIGHT OPERATIONS AND SCREENING

LOCATIONS WITH CASES

COVID-19 CASE COUNT TRACKER

COVID-19 Vaccination Myths vs Facts

ALL COVID-19 VACCINE NEWS

- **VACCINE UPDATE - VACCINATION BEGINS IN AUCKLAND**
New Zealand // 20 February, 2021
Border and managed isolation and quarantine workers in Auckland being vaccinated....
COVID-19
- **EU TO DOUBLE FUNDING TO COVAX**
Germany // 19 February, 2021
Additional €500 million pledged...
COVID-19
- **PFIZER-BIONTECH VACCINE STABLE AT HIGHER TEMPERATURES**
19 February, 2021
New data submitted to regulatory agency...
COVID-19, General Articles
- **JOHNSON AND JOHNSON APPLY TO WHO FOR EUA**
19 February, 2021
Up to 500 million doses could be provided to COVAX...
COVID-19, General Articles
- **VACCINE UPDATE - CAMPAIGN ROLLING OUT IN MORE PREFECTURES, SECOND SHIPMENT DUE**
Japan // 19 February, 2021
The vaccination campaign is underway, with healthcare workers in a dozen prefecture being vaccinated...
COVID-19

2019-nCoV > Scientific Update

SCIENTIFIC UPDATE

INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE

Focussing on immunity and vaccine development

Produced by Dr Doug Quarry

19 February 2021

In this week's summary:

19 February:

PART 1: Mutations and Variants

- 1.1 Coronavirus mutations
- 1.2 The most significant mutations
- 1.3 Summary of the major variants
- 1.4 Where B.1.1.7 variant, first identified in the UK, has been found
- 1.5 Where B.1.351 variant, first identified in the South Africa, has been found
- 1.6 Where P.1 variant, first identified in Brazil, has been found


PART 2: Variant News

- 2.1 South Africa suspends use of AstraZeneca's COVID-19 vaccine
- 2.2 South Africa to start COVID-19 vaccinations with J&J doses
- 2.3 Israel: 94% drop in symptomatic COVID cases after two Pfizer shots
- 2.4 Three Israelis who have recovered from COVID have been reinfected with B.1.351 variant
- 2.5 In vitro immune evasion of the B.1.351 variant (South Africa) to both the mRNA vaccines
- 2.7 Possible new reason for B.1.1.7 increased infectiousness
- 2.7 Keeping up-to-date with variants

16 February:

1. Study suggests AstraZeneca vaccine does not protect against mild/moderate COVID-19
2. Update on the three major variants by Eric Topol
3. Rise in pediatric proportion of Israeli COVID-19 cases over 2020
4. Reinfection warning from the WHO
5. Singapore Airlines becomes second airline to have fully vaccinated crew
6. WHO gives emergency vaccine approval to AstraZeneca/Oxford vaccine
7. AstraZeneca/Oxford vaccine to begin trials in children
8. France recommends single vaccine dose for people who have already had COVID-19
9. Australian churches on collision course with the government over AstraZeneca vaccine
10. Israeli study finds 94% drop in symptomatic COVID-19 cases with Pfizer vaccine
11. Pakistan lab expects Sputnik V doses for commercial sale in a week
12. Two Swedish regions pause AstraZeneca vaccinations after mild side-effects
13. The five key mitigation strategies from the CDC's new guidance to reopen schools

VALUTAZIONE
DEI RISCHI



I principali Tracking dei vaccini a livello globale




VACCINE TRACKERS

McGill University
New York Times
London School of Hygiene and Tropical Medicine
WHO Draft landscape of COVID-19 vaccine candidates
Regulatory Affairs Professional Society
Milken Institute
Artis Ventures
Bloomberg COVID-19 Vaccine Tracker
UNICEF - Vaccine Market Dashboard
CDC Vaccine Tracker - US Only
Statistics and Data COVID-19 Vaccinations Data
ECDC Vaccine Tracker




COVID-19 vaccine doses administered per 100 people, Feb 20, 2021

Total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).



Daily COVID-19 vaccine doses administered per 100 people, Feb 20, 2021

Shown is the rolling 7-day average per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).




Vaccine Trial & Approval Map



COVID-19 vaccine doses administered per 100 people, Feb 20, 2021

Total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).



Le ultime notizie correlate

ALL COVID-19 VACCINE NEWS

1 2 3 4 5 ... >

> VACCINE UPDATE - VACCINATION BEGINS IN AUCKLAND

New Zealand // 20 February, 2021
Border and managed isolation and quarantine workers in Auckland being vaccinated....

COVID-19

> EU TO DOUBLE FUNDING TO COVAX

Germany // 19 February, 2021
Additional €500 million pledged...

COVID-19

> PFIZER-BIONTECH VACCINE STABLE AT HIGHER TEMPERATURES

19 February, 2021
New data submitted to regulatory agency...

COVID-19, General Articles

> JOHNSON AND JOHNSON APPLY TO WHO FOR EUA

19 February, 2021
Up to 500 million doses could be provided to COVAX...

COVID-19, General Articles

> VACCINE UPDATE - CAMPAIGN ROLLING OUT IN MORE PREFECTURES, SECOND SHIPMENT DUE

Japan // 19 February, 2021
The vaccination campaign is underway, with healthcare workers in a dozen prefecture being vaccinated...



VALUTAZIONE
DEI RISCHI

Report

EU TO DOUBLE FUNDING TO COVAX

GERMANY // 19 FEBRUARY, 2021

The European Union (EU) announced today they will put forward another €500 million to the COVAX Facility. The additional funds double their contribution so far, bringing it to €1 billion. Germany has also pledged a further €900 million today. Team Europe is leading the way with contributions to the COVAX Facility, with more than €2.2 billion.

LATEST NEWS

1 2 3 4 5 ... >

> FIRST EVER HUMAN CASES OF H5N8 BIRD FLU

Russia // 21 February, 2021
Seven poultry workers are the first known human cases...
Bird flu other strains, Influenza H5N8

> EBOLA OUTBREAK GROWING IN N'ZEREKORE, ONE CASE IN CONAKRY

Guinea // 20 February, 2021
Suspected and confirmed Ebola cases in Guinea
Ebola

> VACCINE UPDATE - VACCINATION BEGINS IN AUCKLAND

New Zealand // 20 February, 2021
Border and managed isolation and quarantine workers in Auckland being vaccinated....

COVID-19

> SUSPECTED EBOLA CASE UNDER INVESTIGATION

Liberia // 19 February, 2021
Case linked to outbreak in Guinea...
Ebola

> ECDC RECOMMENDATIONS TO CONTROL SPREAD OF COVID-19 IN MINKS




Pandemic Information Webinars

(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars




MERS-CoV Information

MERS-CoV FAQs



MATERIALE DI SUPPORTO ALLA VOSTRA STRATEGIA DI RISPOSTA A COVID-19



[< Back to Previous](#)

Monitoring

[Activate Plan](#)[Corp/All Assets](#)

Location (255) ▾

Last searches

Topic (163) ▾

Last searches

Language (1) ▾

Last searches

Planning

**Please contact your International SOS account manager for more information.*

Infectious (28)

Avian Influenza (H5N1) Avian Influenza (H7N9)
Bird Flu (Avian Influenza) COVID-19
COVID-19 Return to Ops COVID-19 Return to Tr...
Chickenpox (Varicella) Chickenpox Offshore
Cholera Ebola
Ebola Travel Managem... Hand Foot and Mouth ...
Hepatitis MERS-CoV

Vector-borne (5)

Chikungunya Dengue Fever
Malaria Yellow Fever
Zika Virus

Environment (10)

Air Pollution Cyclone
Earthquake Flood
Heat Illness Hurricane
Legionnaires' Disease Snowstorm / Extreme ...
Typhoon Wildfire

Operations (7)

General Information Active Shooter
Bomb Threat Civil Unrest
Explosion Work Related Case
_Travel Risk Managem...

[Scroll down to view more](#)

Search Results: 2567 Resources

[Add](#)[Edit](#)[Unhide](#)[Hide](#)

Refine search with keyword or resource type.

[Show more search options ▾](#)**PIANIFICAZIONE**

COVID-19 Pandemic News & Info



91-DIVOC: An interactive visualization of the ex...




91-DIVOC: An interactive visualization of the ex...




Active Screening Alert Poster




Active Shooter Overview



FAR SI CHE I DIPENDENTI FAMILIARIZZINO CON I VACCINI





Domande frequenti sulle vaccinazioni



SCIENTIFIC UPDATE

COVID-19 OVERVIEW

COVID-19 DATA VISUALISATION

COVID-19 MODELLING

USE OF FACE MASKS BY THE GENERAL PUBLIC

COVID-19 TESTING

COVID-19 TREATMENT

COVID-19 VACCINE

COVID-19 VACCINE FAQs

TRAVEL RESTRICTIONS FLIGHT OPERATIONS AND SCREENING

LOCATIONS WITH CASES

COVID-19 CASE COUNT TRACKERS

COVID-19 VARIANTS

FAQS

EDUCATION AND COMMUNICATION

COVID-19 VIDEOS

MEMBERS Q&AS

TRAVEL ADVICE

COVID-19 Vaccine FAQs

COVID-19 VACCINE FAQs

COVID-19 vaccines have been developed at an unprecedented rate. Over 50 vaccines are in human trials. Some vaccines have received authorisation for use in a small number of countries. Several countries have commenced vaccination of priority groups, and many more are expected to commence in coming months. Almost all countries are in the process of procuring, approving and planning their distribution and administration of vaccine. Meanwhile many vaccine candidates continue to be developed and tested. The situation is dynamic. International SOS is monitoring the situation closely. The latest updates are in the News section of this website and the individual country pages.

Frequently Asked Questions

Is there a vaccine available against COVID-19?

Yes but currently only in a few countries and there is a number of different COVID-19 vaccines now being used. Due to relatively limited supplies, they are in general reserved for high priority groups (such as healthcare workers and elderly people living in aged care facilities). It is expected that as more vaccines are approved, and supply improves, vaccine will be available to more people in more locations. For more information see the Vaccine page of this website.

Do you have a list of countries where vaccination is available?

International SOS is monitoring the information and publishing it on this website for members. Select the country of interest on the Locations page, and scroll down to the "news" section. We hope to be able to publish this in a consolidated table format. If you require more information, contact any International SOS assistance centre or our Health Consulting teams.

Can we purchase vaccine and import it for our employees?

Currently private organisations cannot access vaccine outside of the local national / state processes. Globally, vaccines are considered medical therapeutics, and are governed by national regulations for importation and use. Each jurisdiction has its own requirements. COVID-19 vaccines are expected to be progressively approved, produced and made available under the control of national health authorities in 2020/2021. Authorities are likely to initially control the access and the distribution of the vaccines while supplies are limited.

Can I have one brand for the first shot, and a different brand for the second?

Ideally both doses should be of the same vaccine. Many health authorities, including CDC have said the two vaccines are not interchangeable. However CDC guidance now adds, "In exceptional situations in which the first-dose vaccine product cannot be determined or is no longer available, any available mRNA COVID-19 vaccine may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 vaccination series. If two doses of different mRNA COVID-19 vaccine products are administered in these situations (or inadvertently), no additional doses of either product are recommended at this time." Every effort should be made, however, to use the same product both times as interchangeability has not been evaluated. In the UK, officials state that in the rare event that the same kind isn't available or if it's not known what was given for the first shot, it's OK to give whichever vaccine is available for the second shot. Since the Pfizer and AstraZeneca vaccines work in a similar way, they say a mismatched dose is better than partial protection.

9-vaccine

Most COVID-19 vaccines require two shots, given three to four weeks apart, and the same vaccine

Materiale informative sulle vaccinazioni

COVID-19 VACCINATION

Protect Yourself & The Community

COVID-19 VACCINES ARE SAFE AND EFFECTIVE
All COVID-19 vaccines have to undergo rigorous testing as follows:

3 phases of clinical trials

Approval process of **Stringent Regulatory Authorities**

COVID-19 VACCINATION SAVES LIVES
Vaccination **reduces the risks of infection**, especially severe infection that leads to hospitalisation.

This will help keep our hospitals and healthcare facilities from being overwhelmed.

Vaccinated people are **probably less likely to transmit COVID-19**.

Enough vaccinated people can **reduce the spread**.

The community will **be safer**, especially for those who cannot be vaccinated.

Vaccination can contribute to a **safe & gradual reopening of the economy & society**.

While vaccination is voluntary, all who are medically eligible are encouraged to be vaccinated.

Millions of people have been vaccinated. Reports of serious side effects have been very rare and no long term complications reported.

Seek facts, backed by research and data, published by credible health care providers and organisations. Avoid spreading misinformation.

WHO ECDC CDC

Be aware of scams pretending to provide COVID-19 vaccines. Only participate in vaccination programmes authorised by your local health authorities.

If you have any questions or doubts about COVID-19 vaccination, reach out to your trusted doctors and health providers for clarification.

COVID-19 VACCINATION

MYTHS VS FACTS



COVID-19 VACCINATION

MYTHS VS FACTS

MYTH
I have already had COVID-19 so I don't need to be vaccinated.

FACT
Most authorities advise even people who have had COVID-19 infection to be vaccinated, although you may be advised to wait for at least 90 days after your infection. **Speak to your doctor for an individual recommendation.**

We do not yet know how long the protection from your immunity developed by a COVID-19 infection will last.

COVID-19 VACCINATION

MYTHS VS FACTS

MYTH
The fatality rate of COVID-19 is so low, so I do not need to be vaccinated.

FACT
COVID-19 vaccines protect yourself, your family, colleagues and your community. They reduce the risk of severe infection and hospitalisation. People who are vaccinated are probably less likely to transmit the disease. When the majority of the population are vaccinated it will protect the community, including the vulnerable and those who cannot be vaccinated.

While vaccination is voluntary, all who are medically eligible are encouraged to be vaccinated.

INTERNATIONAL SOS

David Helmerlin...

Monitor / Active Threat: COVID-19

Monitor

Active Threat: COVID-19

Alerts

Locations

Reporting

My Company

Resources

Location Insights

Intelligence & Forecasting

Related Materials

Video Resources

Workforce Education

Educational Materials from International SOS

TRANSMISSION INFOGRAPHIC

Click [HERE](#) to download an infographic highlighting factors to reduce the risk of COVID-19 transmission.

COVID-19 VACCINE BENEFITS

Click [HERE](#) to download an Infographic outlining the key benefits of the COVID-19 vaccination.

COVID-19 VACCINE MYTHS & FACTS

Click [HERE](#) to download a document showing myths versus facts about the COVID-19 vaccine.


CONTACT US



EDUCARE

eLearning e Webinar formativi su misura sulle vaccinazioni

Vaccine Myth Buster
Introduction

A graphic for a micro-learning module titled 'Vaccine Myth Buster'. It features a background image of a healthcare worker in a white coat and blue mask administering a vaccine to a patient's arm. Overlaid on this is a blue banner with the text 'Welcome to this micro learning on: Vaccines'. Below the banner are two circular icons: one showing a pink virus particle and a blue syringe, and another showing a blue smartphone with a pink megaphone icon. At the bottom, a pink banner contains the text: 'This short module is designed to help you understand the critical role that vaccines play in reducing the spread of COVID-19.' The International SOS logo is in the top right corner.



EDUCARE

INTERNATIONAL SOS
David Heimerlin...
Monitor / Active Threat: COVID-19


Monitor
Active Threat: COVID-19
Alerts
Locations
Reporting
My Company
Resources

Location Insights
Video Resources
Video Materials from International SOS

WORKFORCE RESILIENCE 2021 | COVID-19 Vaccines & Variants | Q&A with our Vaccine Lead Dr. Doug Quarry
08 Mar 2021
COVID-19 Va
This is a Web

CONTINUED RESILIENCE AMIDST CRISIS: A REFLECTION ON A YEAR OF COVID-19
04 Nov 2020
Year Review
A reflection o

18 Sep 2020



AGGIORNAMENTI 24/7 CIRCA OGNI NUOVA QUESTIONE LEGATA A COVID



Allerte in tempo reale relative a COVID-19 per i manager

The screenshot displays the International SOS Monitor interface. The top navigation bar includes the International SOS logo, a user profile for David Heimerlin, and a 'CONTACT US' button. The left sidebar contains navigation links: Monitor, Active Threat: COVID-19, Alerts, Locations, Reporting, My Company, and Resources. The main content area is titled 'Monitor' and shows a list of 'Alerts (196)'. The alerts are filtered by 'Security' and 'Advisory' categories. The first alert is for Mauritius, dated 26 Mar 2021 15:23 GMT, with a 'COVID (Travel): Very High' severity. The second alert is for Pakistan, dated 26 Mar 2021 14:45 GMT, with a 'COVID (Domestic Ops): Medium' severity. The third alert is for the Philippines, dated 26 Mar 2021 14:12 GMT, with a 'COVID (Travel): Very High' severity. Each alert includes a 'Read full alert >' link.

INTERNATIONAL SOS

David Heimerlin...

CONTACT US

Monitor

Alerts (196)

Filter options Reset

Date 1 to 10 of 196 records

Security Advisory COVID (Travel): Very High COVID (Domestic Ops): Medium

26 Mar 2021 15:23 GMT - Last updated 5 minutes ago

Mauritius | COVID-19: Continue to defer all travel amid suspension of international flights until 15 April, nationwide lockdown extension until 31 March [more detail +](#)

[Read full alert >](#)

Security Notice

26 Mar 2021 14:45 GMT - Last updated 43 minutes ago

Pakistan | Quetta: Avoid protest outside Press Club on 27 March (Correction) [more detail +](#)

[Read full alert >](#)


Security Notice

26 Mar 2021 14:12 GMT - Last updated 1 hour ago

Philippines | Expect significant disruption, heightened security during Holy Week from 28 March-4 April [more detail +](#)

[Read full alert >](#)

MONITORING



Aggiornamenti sanitari per i manager



Monitor

Active Threat: COVID-19

Alerts

Locations

MONITORING

Neil Nerwich ▾

CONTACT US

Monitor / Active Threat: COVID-19

Location Insights

Intelligence & Forecasting

Related Materials

Scientific Update

Security Analysis & Forecasting

The Scientific Update is a weekly compendium of items relating mainly to immunity and vaccine development.

INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 5 MARCH 2021

Download document

05 Mar 2021 11:00 GMT

INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 2 MARCH 2021

Download document

05 Mar 2021 10:57 GMT

INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 26 FEBRUARY 2021

Download document

26 Feb 2021 09:20 GMT

INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 19 FEBRUARY 2021_SG

Download document

19 Feb 2021 11:10 GMT

Aggiornamenti sanitari per i manager



David Heimerlin...CONTACT US

Monitor / Active Threat: COVID-19

Location Insights

Intelligence & Forecasting

Related Materials

COVID Impact

News & Status

Interactive Data

News & Status

Q Enter a location for specific insights X

COVID-19 News for All Locations

COVID-19 Status for All Locations

26 Mar 2021 - [Bulgaria: Vaccine update - vaccination open to everyone](#)

26 Mar 2021 - [Palestinian Territory: Vaccine Update: Nationwide campaign underway...](#)

26 Mar 2021 - [Nepal: COVID-19 update: Quarantine measures changed for fully vaccinated visitors](#)

26 Mar 2021 - [Austria: Vaccine update - Locally manufactured AstraZeneca supplies rolled out](#)

26 Mar 2021 - [Australia: Community-acquired case in Brisbane](#)

26 Mar 2021 - [Philippines: Healthcare overwhelmed due to COVID-19](#)

26 Mar 2021 - [Study: SARS-CoV-2 can infect the mouth and salivary glands](#)

123...next

Afghanistan	AFG	limited activity
Albania	ALB	outbreak
Algeria	DZA	limited activity
American Samoa	ASM	imported only
Andorra	AND	increasing activity
Angola	AGO	limited activity
Anguilla	AIA	limited activity
Antarctica	ATQ	imported only
Antigua and Barbuda	ATG	decreasing activity
Argentina	ARG	outbreak

123...next

MONITORING

Aggiornamenti sanitari per i manager

pandemic.internationalsos.com/countries/austria

Pandemic PREPAREDNESS

ACTIVE THREATS

- COVID-19 ✓
- Bird flu other strains ✓
- Ebola ✓
- MERS-CoV ✓
- Seasonal Flu ✓
- Influenza G4 EA H1N1 ✓

AUSTRIA

Updated: February 2021

Coronavirus Disease 2019 (COVID-19)

The first cases of COVID-19 were reported in late February 2020, and local transmission was later detected. See the *Latest News* items below.


For general information regarding COVID-19, **helpline is 0800 555 621** which is open 24 hours. If you suspect you are infected, **call 1450**.

Cases: As of 16 February, there are 432,469 confirmed cases and 8,164 deaths since the start of the pandemic. Active cases currently stand at 20,935.

Status: **Outbreak**

Vaccine: The Pfizer/BioNTech COVID-19 vaccine COMIRNATY received [conditional approval \(in German\)](#) from the European Commission in December. Vaccination began on 27 December at the Medical University of Vienna. The highest priority are elderly people and health workers in long-term care facilities.

Websites: View the Government [website \(in German\)](#) for updates on COVID-19 in the country. The national vaccination strategy is [here \(in German\)](#). The country's vaccination dashboard can be found [here \(in German\)](#).




Search

North Atlantic Ocean


South Atlantic Ocean

Indian Ocean


© Mapbox © OpenStreetMap Improve this map



Pandemic Information Webinars



MERS-CoV Information
MERS-CoV FAQs



MONITORING



Pandemic PREPAREDNESS

ACTIVE THREATS

COVID-19



MONITORING




Report

BATCH OF ASTRAZENECA VACCINE SUSPENDED AFTER RECIPIENT DIED

AUSTRIA // 07 MARCH, 2021

Austria's Federal Office for Safety in Health Care (BASG) received reports of one death and one other serious adverse event among people who had received the AstraZeneca COVID-19 vaccine from the same batch. Both patients were vaccinated in the district clinic of Zwettl, in Lower Austria province. A 49-year-old woman died from a blood clotting disorder, and a 35-year-old woman developed a pulmonary embolism (a blood clot in the lungs.) The BASG said, "Currently there is no evidence of a causal relationship with the vaccination.[...] According to current knowledge, the clinical data do not show any worrying data or signals in this respect compared to placebo. [...] At present, all necessary investigations involving the respective experts are running at full speed in order to be able to completely exclude a possible connection. To be on the safe side, the remaining stocks of the affected vaccine batch will no longer be distributed and vaccinated."



pandemic.internationalsos.com/reports/vaccine-update---10-million-more-doses-of-pfizer-vaccine-secured-feb-04-2021

English

Pandemic PREPAREDNESS

ACTIVE THREATS

COVID-19


VACCINE UPDATE - SOME ASTRAZENECA SUPPLIES RECEIVED, ONSHORE SUPPLIES EXPECTED LATER THIS MONTH

AUSTRALIA // 09 MARCH, 2021


9 March: Phase 1A of the vaccination campaign continues - so far over 86,000 people have received a dose of vaccine. Some supplies of the AstraZeneca vaccine have been received, and the first vaccinations with this brand started in South Australia. However supplies from overseas have been delayed as the European Commission has refused to authorise export of the vaccine. The first doses of locally-produced AstraZeneca vaccine (manufactured onshore by CSL) will be available by the 22 March - the plan is to produce a total of 50 million doses.

In February, a doctor who was vaccinating residents of an aged-care facility in Brisbane inadvertently administered an excessive amount of vaccine.


23 February: Vaccination campaigns kicked off in Australia on 22 February in **Australian Capital Territory, New South Wales, Northern Territory, Queensland, South Australia, Victoria** and **Western Australia**. On the first day, there were around 1,300 doses administered in **New South Wales**, 580 in **Victoria** and over 200 in **Queensland**.



© Mapbox © OpenStreetMap Improve this map



Pandemic Information



MERS-CoV Information

MONITORING

COVID-19 Impact Scale e Restrizioni di Viaggio



Consigli per i viaggi internazionali e nazionali, in entrata e in uscita
Strumento: COVID Impact Scale

The screenshot shows the International SOS COVID Impact Scale web application. The interface includes a sidebar with navigation options: Monitor, Active Threat COVID-19, Alerts, Locations, Reporting, My Company, and Resources. The main content area is titled "Monitor / Active Threat: COVID-19" and features three tabs: Location Insights, Intelligence & Forecasting, and Related Materials. Under Location Insights, there are three sub-tabs: COVID Impact, News & Status, and Interactive Data. The COVID Impact sub-tab is active, displaying the "COVID Impact Advisor" section. This section includes a search bar with filters for "United States - All States", "United Kingdom", "Japan", and "Australia". Below the search bar, there are options to "Show Last 24 Hours" and "Filter Options", along with a "Run Report" button. The main content area displays the "Australia" section, showing the "COVID Impact Rating (Travel): High" and "COVID Impact Rating (Domestic Operations): Low". A link to "View All Definitions" is also present. Below the ratings, the "Restrictions" section is visible, detailing inbound travel restrictions for Australia.

Australia

COVID Impact Rating (Travel): High ⓘ

COVID Impact Rating (Domestic Operations): Low ⓘ

[View All Definitions](#)

Restrictions


Inbound

All non-resident travellers are banned from entering Australia. Only travellers who fit in the following categories are allowed to enter Australia without obtaining an individual exemption

- an Australian citizen
- a permanent resident of Australia
- an immediate family member of an Australian citizen or permanent resident*
- a New Zealand citizen usually resident in Australia and their immediate family members
- a person who has been in New Zealand for 14 days or more immediately prior to arrival by air in Australia
- a diplomat accredited to Australia, including their immediate family members (each member of the family unit must hold a valid subclass 995 visa)
- a person transiting Australia for 72 hours or less
- airline crew, maritime crew including marine pilots



MONITORING



Informazioni sulla pandemia di Covid-19 tramite aggiornamenti via e-mail



Pandemic Update 17 February 2021



International SOS <pandemic_updates@learn.international
To: Neil NERWICH MD



Wed 17/02

Must Attend

If there are problems with how this message is displayed, click here to view it in a web browser.

PADEMIC INFORMATION



Update - 17 February 2021

Dear Neil

In this edition:

- COVID-19
- Ebola
- MERS-CoV
- Avian influenza

Highlights

- [B.1.1.7 from the UK may be more deadly - NERVTAG update](#)
- [CDC - fully vaccinated people do not need to quarantine after exposure](#)
- [Ebola outbreak declared in Guinea](#)

COVID-9 vaccination has recently begun in the following countries:


- [Cambodia](#)
- [Dominica](#)
- [Lebanon](#)

COVID-19


Since the last Pandemic Update on 10 February, the number of new cases reported has slowed. Globally, there are 110 million cases and over 2.42 million deaths.




MONITORING






ASSICURARSI CHE IL PROPRIO STAFF SIA BEN INFORMATO






Allerte e informazioni su COVID-19 via App





Supporto per le vaccinazioni Covid-19 su chiamata

- Informazioni e consigli per i manager da parte di professionisti sanitari
- Le questioni più complesse possono essere affidate ai nostri consulenti



International SOS AC COVID Tracker Germany

Data last refreshed: 18/02/2021 06:05 UTC

Int'l SOS Pandemic Status: Outbreak

Latest Data: 15/02/2021

Total Cases: 2,352,766 (Prev Day: 2,346,876 (+0.25%))

New Case 7DA: 7,245 (Prev Day: 7,222 (-0.32%))

Vaccine Program Start: 27/12/2020

Vaccines Available: MD, OX/AZ, P/BN

Gov. Roll-out Policy: 2G

Case trend over last 28 days: -32.98%

Total Vaccinations: 4,284,554 (Prev Day: 4,162,766 (+2.93%))

Days since last case: 0

Daily Vaccinations (7DA): 123,616 (Prev Day: 120,305 (+3.31%))

% Vaccinated / day (7DA): 0.15% (Prev Day: 0.14% (+0.00%))

Medical Risk Rating: Low

Travel Risk Rating: Low

Travel Impact Scale: High

Domestic Impact Scale: Low

Do non-nationals have access to vaccine? Yes all people living in Germany have access to vaccine independently of

Medical Country Guidance

1. Guidance for symptomatic individuals, National Hotline(s) & Online Symptom Checkers
Symptomatic patients should contact their local GP, the local health authority ("Gesundheitsamt") - see Link 4 for website details and insert the person's postcode). Alternatively, patients can call the national-wide number using cell phone only: 116117 (Kassenärztlicher Notdienst) for further support. This is not an emergency number but can help with medical orientation. The automated phone system will request the postcode, which will then need to be entered, to provide nearest provider in their location. Emergencies should call 112. See Link 7. Ministry of Health - Link 1 and Robert Koch Institute COVID-19 o

2. Impact on Healthcare system
Nil information obtained at the moment, the health system is stressed but still working.

3. Designated COVID-19 Providers for Treatment
Private HCD services can also provide medical advice (via consultation).

4. National Testing Capabilities
Many districts have central test centers. Generally, private laboratories can do tests but the medical need shall be co available (no antigen testing) in approved laboratories only, samples taken from Drive-thru clinics, GP practice and h

Testing requires a referral from a clinician and to meet the testing criteria: fever, acute respiratory infection (e.g. short confirmed case, been recently abroad. Cost is 200 EUR. Turnaround time for results 24-48 hrs.

Private PCR tests and Antibody tests are available and have become part of the official testing strategy. Link 12. Link

COVID: Travel Restrictions

Restriction	Ends	Detail
Inbound travel	3 March 2021	Entry restrictions: A) Inbound travel for European nationals: European nationals are able to enter Germany. B) Inbound travel for "third-country" nationals: Germany allows unrestricted entry for residents of Australia, New Zealand, Singapore, South Korea and Thailand. Third-country nationals are permitted to enter Germany if they are skilled and highly qualified foreign workers whose employment is necessary from an economic perspective and whose work cannot be postponed or performed abroad. The categories of permitted travellers can be reviewed at https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/which-skilled-and-highly-qualified-foreign-workers-are-permitted-to-enter-Germany.html Third-country nationals with residency are allowed to enter. This includes those with student visas. Additionally, some allowances are made for family matters: https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/travel-restriction-border-control-list.html#14104798 C) Inbound travel for COVID-19 variant areas: Germany has imposed a general ban on travel and entry from countries with widespread occurrence of COVID-19 variants. At present, this includes Austria (only Tyrol state), Botswana, Brazil, Czech Republic, Eswatini, Ireland, Lesotho, Malawi, Mozambique, Portugal, South Africa, the UK, Zambia and Zimbabwe. This is in place until at least 3 March. This ban does not cover German citizens and residents or those transiting German airports. D) Border closures: All of Germany's borders remain open. Since Tyrol state (Austria) and the Czech Republic are rated as COVID-19 variant areas, border checks are in place for land movements to enforce the respective restrictions.

Airport Precautionary Measures

Frankfurt: <https://www.frankfurt-airport.com/en/transfer-at-frankfurt-airport/covid-19/safety.html>

Düsseldorf: <https://www.dus.com/en/services/unbesorgt-starten>

Munich: <https://www.munich-airport.com/travelling-in-times-of-the-coronavirus-pandemic-8395611>

Dresden / Leipzig: <https://www.mdf-ag.com/presse/pressemitteilungen/details/reisehinweis>

Hamburg: https://www.hamburg-airport.de/en/current_information.php#

Berlin: <https://www.berlin-airport.de/en/company/latest-news/news/2020/2020-06-10-fliegen-corona/index.php>

Entry/Transit Requirements

<https://www.auswaertiges-amt.de/en/einreiseundaufenthalt/coronavirus>


Digital Entry Application (DEA): <https://www.einreiseanmeldung.de/>

<https://www.lufthansa.com/de/en/entry-into-germany/risk-level>


https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Risikogebiete_neu.htm

Entry from high risk areas
All travellers to Germany from a level 2 risk area must present a negative Corona/Covid-19 test upon departure. The proof of the negative Corona/Covid-19 test must not be older than 48 hours at the time of entry and is checked by the transport


PRESA DI DECISIONI INFORMATE



FORNIRE SUPPORTO ALLO STAFF



Riferimenti e disposizioni per le vaccinazioni, se disponibili



The image displays three screenshots of the SPIN 7.0 N2 web application interface, which is used for searching and managing COVID-19 related services and vaccine providers.

Top Left Screenshot: Shows the search results for "COVID 19 Rapid Diagnostic Test (Antigen)". The results list providers such as "GP Plus Ltd (12737)" and "London Doctors Clinic Covent Garden (145033)". A map of the United Kingdom is visible on the right.

Top Right Screenshot: Shows the search results for "COVID 19 Vaccine (Pfizer-BioNTech)". The results list providers such as "GP Plus Ltd (12737)" and "London Doctors Clinic Covent Garden (145033)". A map of the United Kingdom is visible on the right.

Bottom Screenshot: Shows the "Quick Search" form with various filters. The "Specialty (Inclusive)" dropdown is set to "Covid". The "Provider Family" dropdown is set to "SOS Pandemic Management". The "Provider Category" dropdown is set to "Select All". The "Provider Type" dropdown is set to "Select All". The "Program" dropdown is set to "SOS Pandemic Management". The "Care Area" dropdown is set to "Select All". The "Customer" dropdown is set to "SOS Pandemic Management". The "Preferred Pricing Indicator" dropdown is set to "Select All". The "Rank" dropdown is set to "FC + P + C". The "Search" button is highlighted with a red circle.

Bottom Left Screenshot: Shows the "Quick Search" form with various filters. The "Specialty (Inclusive)" dropdown is set to "Covid". The "Provider Family" dropdown is set to "SOS Pandemic Management". The "Provider Category" dropdown is set to "Select All". The "Provider Type" dropdown is set to "Select All". The "Program" dropdown is set to "SOS Pandemic Management". The "Care Area" dropdown is set to "Select All". The "Customer" dropdown is set to "SOS Pandemic Management". The "Preferred Pricing Indicator" dropdown is set to "Select All". The "Rank" dropdown is set to "FC + P + C". The "Search" button is highlighted with a red circle.

**SUPPORTO E ASSISTENZA
AI DIPENDENTI**

SONDAGGIO

Vuoi saperne di più su come International SOS può supportare la tua azienda per ottenere sempre informazioni accurate e tempestive e attraverso quali strumenti?

- Si
- No



VACCINAZIONI ANTI COVID-19 | SERVIZI DI SUPPORTO

Pianificazione e implementazione della vostra strategia vaccinale



Programmi vaccinali:
fornitura e
amministrazione



SUPPORTO E
ASSISTENZA AI
DIPENDENTI



PRESA DI
DECISIONI
INFORMATE



INFORMARE
LO STAFF



VALUTAZIONE
DEI RISCHI




PIANIFICAZIONE




EDUCARE



MONITORING
DELLE
MINACCE



Consulenza sulla strategia
e la pianificazione delle
vaccinazioni anti
COVID



Strategia e pianificazione vaccinale

Servizi di Consulenza



Accesso alla nostra rete globale di consulenti sanitari per supportare la vostra pianificazione vaccinale, che comprende:

- **Consulenza strategica** personalizzata per località e profili dei dipendenti
- **Monitoraggio delle vaccinazioni e informazioni sul programma nazionale vaccinale**
- Programmi di **formazione e istruzione sui vaccini**
- Strategie di **consegna dei vaccini**



VALUTAZIONE DEI
RISCHI E
PIANIFICAZIONE

1.

Monitoring

Informazioni sullo stato del vaccino, sulla disponibilità del Paese, analisi delle informazioni

2.

Educare

Superare l'esitazione verso il vaccino

3.

Preparare

Revisione del processo e dei protocolli, analisi dei GAP

4.

Approvvigionamento

Supporto con la domanda di richiesta

Data last refreshed: 24/03/2021 18:02 UTC

IntlSOS Pandemic Status Limited Activity	Latest Data 23/03/2021	Vaccine Program Start 22/02/2021	Vaccines Available Ox/AZ, P/BN	Gov. Roll-out Policy 2G	Vaccine Pipeline				
Total Cases 29,221 Prev: 29,211 (-0.03%)	New Case 7DA 10 Prev: 11 (+9.46%)	Total Vaccinations 307,525 Prev: 282,184 (+8.98%)	Total Vaccinations /100 1.21 Prev: 1.11 (+0.10)	Mo to 70% Pop Vacc 66	Vaccine	Approval?	Doses Purchased	Doses needed for regimen	% Vaccine Coverage
Daily Vacs (7DA) 17,870 Prev: 16,772 (+1,098)	% Vacc /day (7DA) 0.07% Prev: 0.00 (+0.00%)	People Fully Vacc	People Fully Vacc /100	Vacc vs Case Grip Ratio	Oxford / AstraZenec...	Approved with conditions	53,800,000	2	105%
					Pfizer/Biontech	Approved with conditions	20,000,000	2	39%
					COVAX Facility (GAVI)			2	
					CSL			2	
					Novavax (NVX-CoV2)		51 000 000	2	100%
					Total		124,800,000		245%

Health Consulting Vaccine Advisory

Overall advisory from Health Consultant

Phase 1B commenced 22 March, with the first of 1,000 GP practices starting to vaccinate. COVID-19 vaccine rollout update on 22 March 2021 <https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-on-22-march-2021>

The Therapeutic Goods Administration (TGA) has approved local manufacture of the AstraZeneca vaccine by CSL-Seqirus in Melbourne <https://www.tga.gov.au/media-release/tga-approves-csl-seqirus-manufacture-astrazeneca-covid-19-vaccine-australia>.

In relation to the suspension of the use of AstraZeneca vaccines by some countries, the Australian Technical Advisory Group on Immunisation (ATAGI) issued a statement <https://pandemic.internationalosos.com/reports/who-advises-vaccination-with-astrazeneca-should-continue-mar-13-2021> saying "Based on evidence to date, ATAGI do not see any reason to pause use of the AstraZeneca vaccine in Australia." They noted "the rates of thrombotic events are not higher in vaccine recipients than the expected background rate" but are monitoring the situation.


The vaccination program started on 22 February. Vaccination is provided free of charge.

Attribute	Value
Possibility for employers to actively offer Covid-19 vaccination to their employees as of now	Evolving
Non-national access to vaccines (comment)	Yes permanent residents and temporary visa-holders
International SOS recommendation on running vaccination communication	Not thought appropriate
International SOS recommendation on running vaccination programme	May become appropriate later
WHO assess countries need assistance to implement vaccination	No
Confidence of healthcare to	Very Confident

Vaccine Programme Summary

Attribute	Value
Date of vaccine programme start	2/22/2021
Comments	Vaccinations with Pfizer began 22 Feb, and AZ 5 March. Group 1b started 22 March with the first of 1,000 GP practices https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-on-22-march-2021
Vaccination Programme (official references)	🔗
Vaccination Programme (other references)	🔗
Type of Rollout	
Vaccination Policy (URL)	🔗
Communication links	
Detail of specific groups	
How do you get vaccine	Some GP Practices are contacting their eligible patients. People can check their eligibility at the website https://covid-vaccine.healthdirect.gov.au/eligibility , which takes eligible people through to identifying clinic and making a booking GP clinics can be found on this list https://www.health.gov.au/resources/publications/covid-19-vaccination-phase-1b-rollout , or through entering your postcode here https://covid-vaccine.healthdirect.gov.au/booking/?sid=b60c14c083636bec11fcb17cbbdfa5206ded7232
Vaccination Record	Australians can already access their immunisation history statement through Medicare for proof of vaccination, both digitally and in hard copy, if required. Statements can be viewed on an individual's Medicare online account or via the Medicare app. Your immunisation history statement will record your COVID-19 vaccinations, following each dose. News 6 Feb: vaccination recorded in Australian Immunisation Register certificate is emailed
Other comments	5 March - presentation for requirements for 1B rollout Presentation - initial towns for phase 1 A rollout https://www.health.gov.au/resources/publications/priority-groups-for-covid-19-vaccination-program-phase-1b

VALUTAZIONE DEI
RISCHI E
PIANIFICAZIONE



Programmi Vaccinali

Fornitura e gestione



Mentre la situazione si evolve progressivamente, continuiamo a mantenerci in contatto con i produttori di vaccini e le autorità sanitarie nazionali.

Quando l'accesso e la distribuzione saranno disponibili per il settore privato aziendale, saremo in prima linea per **sostenervi nella fornitura e nella somministrazione del vaccino ai vostri dipendenti.**



VALUTAZIONE DEI
RISCHI E
PIANIFICAZIONE

1. Trasporto, stoccaggio, distribuzione

Impianti della catena del freddo,
sicurezza dello stoccaggio,
deterioramento

2.

Screening

Idoneità vs. esclusione

3.

Fornitura

Amministrazione, controllo, staffing
e documentazione

4.

Follow Up

Processo di restituzione in 2
settimane

5.

Affaticamento (NPI)

Indossare la mascherina,
distanziamento, lavarsi le mani

6.

Viaggi

Quando e come farli, aiuto pratico

7.

Turismo Vaccinale

Dove potrebbero recarsi presto i
vostri dipendenti

SONDAGGIO

Vi sentite pronti per lanciare una campagna vaccinale aziendale, in ambito di pianificazione e strategia, o vi manca ancora qualcosa?

- **Si, non appena possibile siamo pronti**
- **Ci mancano informazioni accurate / strumenti adatti**
- **Ci manca supporto sul lato pratico (fornitura, competenze, ecc.)**
- **No, non ci sentiamo pronti e vorremmo saperne di più / ricevere supporto**



VACCINAZIONI ANTI COVID-19 | SERVIZI DI SUPPORTO

Un programma completo dalla pianificazione all'esecuzione quotidiana





INTERNATIONAL
SOS

Grazie per l'attenzione!
Per qualsiasi domanda compila il
Questionario di Feedback o contatta:
Italy@internationalsos.com

Scarica la tua copia del documento FAQ sul tema
«Vaccinazioni anti COVID-19 e Chiarimenti Legali per l'Italia»: QUI